M&A: Page 14
-
Roundup: Medtronic's HVAD recall problems continue following patient injuries, deaths
One year after Medtronic pulled the heart pump off the market, there have been two Class I recalls following reports of patient injuries and deaths. Here is a collection of MedTech Dive's coverage of the HVAD saga.
Updated June 27, 2022 -
Courtesy of Humana
Humana acquires Onehome to pursue value-based home health strategy
The deal for Miramar, Florida-based Onehome follows the insurer's recent purchase of home health giant Kindred at Home for $5.7 billion.
By Rebecca Pifer • June 15, 2021 -
Health data giants Ciox, Datavant merge in $7B deal
Real-world health data company Datavant and health record IT firm Ciox Health say combining forces will result in the largest health data ecosystem in the U.S. The merger is supported by investors including J&J and LabCorp.
By Rebecca Pifer • June 10, 2021 -
Medtronic's HVAD controversy
Medtronic's HeartWare HVAD ending brings questions about $1B acquisition
Nearly five years after Medtronic's buy of HeartWare International, the medtech giant pulled the flagship product of the deal due to safety risks, ceding the market to rival Abbott.
By Ricky Zipp • June 8, 2021 -
Abiomed buys preCARDIA to bag breakthrough heart failure device
William Blair analysts had hopes the buy could help Abiomed move past "two years of commercial disruptions" to drive long-term growth.
By Nick Paul Taylor • June 2, 2021 -
Medtronic steps up robotics bet as its challenger to Intuitive starts clinical trial
The medtech giant seeks to double or triple sales in its 2023 fiscal year. However, analysts warned that near-term investments will pressure margins in the short term.
By Nick Paul Taylor • May 28, 2021 -
Adeline Kon/Healthcare Dive/MedTech Dive
PerkinElmer inks $155M Immunodiagnostic buyout, continuing deal spree
The flurry of M&A means PerkinElmer has struck more deals, at a higher aggregate value, in the first six months of 2021 than in the years since it bought Euroimmun for $1.3 billion in 2017.
By Nick Paul Taylor • May 18, 2021 -
Alex Wong via Getty Images
FTC asks Allergan Aesthetics, Soliton for additional information on proposed $550M buyout
The regulator's second request for documentary material, which comes three months after the proposed deal was announced, is part of a deeper probe than its standard review of M&A.
By Nick Paul Taylor • Updated Aug. 11, 2021 -
Mario Tama via Getty Images
NeoGenomics inks $390M Inivata buyout to enter liquid biopsy space
William Blair analysts wrote that NeoGenomics got a good price by setting the buyout fee last year.
By Nick Paul Taylor • May 6, 2021 -
Alex Wong via Getty Images
LabCorp inks $150M takeover of Myriad Genetics autoimmune testing unit
The diagnostics giant discussed its interest in M&A last week, outlining plans to use up to $2 billion in free cash flow to strengthen its businesses through acquisitions.
By Nick Paul Taylor • May 4, 2021 -
MIND_AND_I/iStock / Getty Images via Getty Images
Illumina sues European Commission to block competition probe into Grail buyout
The EU probe is the latest glitch in the takeover bid, which was panned by Wall Street and also faces scrutiny from the FTC. Analysts have said Exact Sciences could benefit from delays.
By Nick Paul Taylor • April 30, 2021 -
Boston Scientific sees Q1 electives rebound, hints at further 2021 M&A
With two acquisitions already in 2021, CFO Daniel Brennan said, "We have the appetite, and we have the balance sheet in place to continue to" spend later this year.
By Ricky Zipp • April 28, 2021 -
Adeline Kon/MedTech Dive
Moody's predicts brisk pace of medtech M&A amid earnings optimism
A new report from the ratings agency echoes initial commentary by bellwethers J&J and Edwards, which released financials this week.
By Susan Kelly • April 22, 2021 -
Yujin Kim/MedTech Dive
Robotics startup Vicarious raises $425M, including from BD, to take on giants
Aiming for a 510(k) submission in 2023 and to grow sales to $1 billion by 2027, the firm with high-profile backers including Bill Gates will face competition from Intuitive, J&J and Medtronic.
By Nick Paul Taylor • April 16, 2021 -
Thermo Fisher to buy research contractor PPD for $17.4B
The deal comes months after a failed attempt by the company to acquire molecular diagnostics company Qiagen.
By Kristin Jensen • April 15, 2021 -
Italy's DiaSorin buys Luminex in $1.8B deal for multiplex molecular testing assets
The takeover comes weeks after Roche agreed to pay $1.8 billion to buy GenMark Diagnostics for its multiplex testing capabilities. The two targets compete with BioFire and Quidel.
By Nick Paul Taylor • April 12, 2021 -
Hologic pens $795M Mobidiag buyout to expand in acute care testing
Wall Street analysts cheered the move, with Evercore ISI writing "it fills a major hole in the company's armament." The deal marks Hologic's fourth pick-up of 2021, including the $230 million takeover of Biotheranostics in January.
By Nick Paul Taylor • April 9, 2021 -
LumiraDx lands on Nasdaq via SPAC with aim to undercut Abbott on price
The COVID-19 test maker hopes to generate enough capital to pursue a point-of-care testing opportunity it values at $76 billion. It has a ways to go to deliver.
By Nick Paul Taylor • April 8, 2021 -
Invitae inks $200M Genosity buyout, lands $1.2B investment to expand genetic testing
The medical genetics company expects Genosity's capabilities to increase access to its cancer test and reduce turnaround time, while a sizable investment led by SoftBank will support growth initiatives.
By Nick Paul Taylor • April 6, 2021 -
Courtesy of Quest Diagnostics
Quest sells minority share of Q2 Solutions for $760M
IQVIA, which previously owned 60% of Q2 Solutions, will now become the sole owner of the clinical trials laboratory company. Quest and IQVIA established Q2 Solutions as a joint venture in 2015.
By Ricky Zipp • April 1, 2021 -
Roche to buy GenMark for $1.8B to add multiplex testing
The Swiss company said the deal will give it access to a novel technology for testing a range of pathogens with one patient sample. William Blair analysts expect "potentially intense bidding wars" in the sector in coming months.
By Greg Slabodkin • March 15, 2021 -
Cardiac wearables, iRhythm, under a cloud as reimbursement questions linger
"If this [Novitas Solutions] rate is not adjusted, these companies don't make money and will be unlikely to provide the service," Baird analyst Mike Polark said.
By Ricky Zipp • March 15, 2021 -
Cardinal Health sells troubled Cordis unit to private equity firm for $1B
Hellman & Friedman's acquisition of the maker of interventional vascular technology follows Cardinal's 2015 buy of Cordis from Johnson & Johnson for $1.9 billion.
By Greg Slabodkin • March 12, 2021 -
Colfax to split in 2, creating over $1B orthopaedic player
The split will create a medtech company with a portfolio of orthopaedic devices forecast to generate sales of around $1.4 billion this year. The move is expected to facilitate more M&A.
By Nick Paul Taylor • March 8, 2021 -
Warchests, distressed assets drive medtech M&A flurry early in 2021
The industry is averaging more than one $100 million-plus takeover a week, as the influx of COVID-19 test revenues and pressures on companies reliant on surgical procedures create buying opportunities.
By Nick Paul Taylor • March 5, 2021
Previous
